Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NNC0662-0419
- Development stage
- Phase 2
- Lead developer
- Novo Nordisk
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
NNC0662-0419 is an investigational triple agonist peptide designed for the treatment of obesity and overweight. It acts as an agonist at three key metabolic hormone receptors: the glucagon receptor (GCGR), gastric inhibitory polypeptide receptor (GIPR), and glucagon-like peptide 1 receptor (GLP-1R). By simultaneously activating these receptors, NNC0662-0419 aims to enhance weight loss through multiple mechanisms including appetite suppression, increased energy expenditure, and improved glucose metabolism. The drug is being developed by Novo Nordisk and is currently in Phase 1 clinical trials as a once-weekly subcutaneous injection in adults with overweight or obesity[1][4][5]. This is its first evaluation in humans.
02
Targets
Beyond the preview
Go deeper on NNC0662-0419.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NNC0662-0419.